, Tracking Stock Market Picks
Enter Symbol:
Opexa Therapeutics, Inc. (OPXA) [hlAlert]

Mkt Outperform
down 95.81 %

Opexa Therapeutics, Inc. (OPXA) rated Mkt Outperform with price target $6 by Rodman & Renshaw

Posted on: Tuesday,  Mar 30, 2010  8:25 AM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform Opexa Therapeutics, Inc. (NASDAQ: OPXA) on 03/30/2010, when the stock price was $9.08.
Since then, Opexa Therapeutics, Inc. has lost 95.81% as of 01/26/2016's recent price of $0.38.
If you would have followed this Rodman & Renshaw's recommendation on OPXA, you would have lost 95.81% of your investment in 2128 days.

Opexa Therapeutics, Inc. develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin, a T-cell therapy for multiple sclerosis is in Phase IIb trials. The Company holds the exclusive worldwide license for adult multipotent stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is in preclinical development for type one diabetes.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/30/2010 8:25 AM Buy
9.08 24.00
as of 12/31/2010
1 Week up  59.63 %
1 Month up  90.64 %
3 Months up  73.20 %
1 YTD up  16.74 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy